zation predicts that by the year 2020, COPD will be the third leading cause of death globally. 3 In a recent cross-sectional study of hospitalizations of 122,630 US Medicare HF beneficiaries, pulmonary comorbidities, including COPD, asthma, and other lower respiratory tract diseases, showed the highest readmission rates among the 18 chronic disease categories surveyed. 1 It was concluded that new onset or undiagnosed comorbid conditions in HF patients may be overlooked and thus precipitate, complicate, and contribute to hospital admissions. With the population living longer and the increasing incidence of both HF and OLD, it is not surprising that airflow limitation is an independent predictor of cardiovascular events in persons with a history of cardiovascular risk factors. 4 OLD is a term describing the manifestation of reactive airway limitation or obstruction, encompassing both asthma and COPD. 5 COPD includes 2 diagnostic categories of airway obstructionchronic bronchitis and emphysema. While the epidemic of asthma is greatest in childhood (10% of the population, with 5 million new cases added annually), a resurgence of increased airway responsiveness often follows in later life, affecting 7% to 9% of the adult and elderly population. 6 This recurrence is
In the NHANES III study, it was postulated that 14.3 million people in the United States have OLD, with an estimated equal number of cases remaining undiagnosed. 5 Significant predictors of low lung function include being an active smoker, leading a sedentary lifestyle, and having cardiovascular disease. The data further confirm the associations of advancing age with OLD, and low lung function with a decreased life span. 5 Clinicians should note that 63.3% of those found to have OLD in the NHANES III study were undiagnosed prior to the survey.
Thus, the HF practitioner is often faced with either or both of the following situations: (1) evaluating a new patient with dyspnea and cough, and developing differential diagnoses of HF and/or OLD or other possible etiologies; and (2) evaluating a known HF patient with coexistent OLD and determining which disease exacerbation underlies the current symptoms. The purpose of this article is to provide the HF practitioner with practical information about how to make these distinctions and how to develop a treatment plan for the HF patient that incorporates important information about OLD. The pathophysiology of OLD and HF will be reviewed first. This will be followed by details on the assessment of dyspnea and the management of acute exacerbations of OLD. Finally, pharmacologic issues in the management of concomitant HF and OLD will be reviewed.
Pathophysiology of OLD and HF
Two key components of both asthma and COPD focus on the roles of airway inflammation and smooth muscle dysfunction leading to airway remodeling. Asthma is defined as an inflammatory disorder of the airways, characterized by increased airway responsiveness and airflow limitation, which is variable in nature. 8 The airways show vasodilation, smooth muscle hypertrophy, and submucus gland hyperplasia, accompanied by edema of the submucosa and mucosa. These airway structures are infiltrated with eosinophils, T cells, mast cells, and neutrophils. This environment limits airflow and becomes hyperresponsive, favoring bronchoconstriction in response to stimuli. 6 Extrinsic triggering agents include exercise, cold air exposure, allergens, pollutants, foods, medications, tobacco or smoke, and respiratory tract infections. There can also be an intrinsic component related to heredity, as evidenced by a coinheritance of genes for atopy and bronchial hyperresponsiveness. 9 Poorly controlled acute and chronic asthma is known to cause irreversible damage to airway structures via a remodeling process. This remodeling contributes to the declining lung function and is manifest as the OLD of asthma that persists in later life. 7 The current definition of COPD is the product of an international committee called the Global Initiative for Chronic Obstructive Lung Disease, which produced the GOLD Guidelines for the diagnosis and treatment of COPD. COPD is defined as a disease state characterized by airflow limitation that is not fully reversible, usually progressive, and associated with an abnormal inflammatory response in the lungs in response to noxious particles or gases. 10 Ninety percent of the inflammation that causes airflow limitation is due to cigarette smoke. The remaining 10% is attributed to air pollution, occupational exposure, passive smoking, genetic factors, and chronic respiratory infections during childhood. 6 The inflammatory airway response is classified as a neutrophilic bronchitis, triggering macrophages and neutrophils to release harmful chemical mediators responsible for some of the chronic lung remodeling and destruction in COPD. 3 Inflammation from these pathologic changes results in varying amounts of mucus secretion, producing cough in an effort to clear the obstruction. In emphysema, there is destruction of the interalveolar septa, leading to lung hyperinflation and decreased diffusion capacity. Both result in airflow limitation or collapse, with air trapping, hyperinflation, and a prolonged expiratory phase of respiration. 3 Just as airway remodeling occurs in OLD, the process of ventricular remodeling underlies the development of chronic systolic HF. Remodeling involves hypertrophy of the ventricular myocytes and regression from an adult to a fetal phenotype, which leads to large, genetically abnormal cells that cannot contract as efficiently as normal myocardial cells. Further changes also occur in the interstitium with fibrotic infiltration leading to a stiffened, less compliant myocardial wall. The myocyte hypertrophy that occurs is associated with cellular disorganization, which leads to a disruption of contractile elements; thus, the myocytes become less efficient despite their larger size and cause an increase in wall stress and oxygen demand. 11 Many neurohormonal systems are activated in HF and further potentiate the remodeling process. Molecules involved in this activation include norepinephrine, angiotensin II, aldosterone and vasopressin. In chronic HF, longterm sustained activation of these neuroendocrine systems is associated with adverse effects and disease progression.
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Assessment of Dyspnea
Patients experiencing disorders in cardiopulmonary function often present with a complaint of dyspnea.
The cause of dyspnea in HF patients with a known or unknown pulmonary comorbidity may be clinically challenging to ascertain. Dyspnea is a subjective complaint related to the awareness of breathlessness and subsequent discomfort associated with the act of breathing. 13 Treatment is dictated by a determination of the underlying physiological cause. If the dyspnea is chronic and progressive, a thorough investigation of the symptom should be conducted, examining such key characteristics as quality, intensity, duration, frequency, associated context of activities that precipitate or exacerbate the dyspnea, and the level of distress.
Assessment of chronic progressive dyspnea in the clinic setting would include typical screening questions regarding family history of asthma, COPD, tuberculosis, allergies, or hay fever. A history of childhood asthma, nasal polyps, recurrent sinus infections, frequent upper respiratory tract infections, pneumonia, or bronchitis is also important to access. Query the patient regarding the number of hospitalizations or emergency department visits for breathing problems in the last 5 years. A thorough smoking history and occupational history can provide valuable clues to the etiology of dyspnea.
Overlapping or concomitant causes of dyspnea, such as HF, asthma, and COPD, further reinforce the need to uncover the precipitating factors to treat the underlying cause. If HF is suspected, dyspnea associated with orthopnea, edema, abdominal bloating, sudden weight gain, and feelings of air hunger may be present. Wheezing, rhinitis, chest tightness, and early morning worsening of symptoms are often related to asthma. COPD would be suspect in instances with increased sputum production from chronic cough and increased fatigue related to the work of breathing. In all 3 cases, dyspnea may be reportedly worse at night and accompanied by cough and wheezing. Failure to uncover the concomitant causes of dyspnea may not only result in worsening of symptoms, but may also result in otherwise preventable hospitalizations. 8, 14 The dyspnea workup will vary according to the information known about the patient's illnesses, as well as the severity of the dyspnea. If dyspnea is being evaluated in a clinic setting, as may occur during the initial evaluation of a HF patient, the workup is more extensive, with results not necessarily needed emergently. The most important diagnostic test to be performed early in the workup is an assessment of left-ventricular function, which is usually obtained via an echocardiogram. 15 However, it can also be obtained from a multigated acquisition study or cardiac catheterization. This assessment is critical not only to determine whether the patient has left-ventricular dysfunction, which can lead to HF, but also to determine whether the patient has systolic dysfunction or HF with preserved systolic function. 16 Any patient who has been thought to have a primary pulmonary cause of dyspnea, but whose symptoms have persisted despite appropriate treatment, should have an assessment of left-ventricular function. Too many patients are treated for asthma for prolonged periods of time when indeed they have later been found to have HF as the primary cause of their symptoms.
A chest x-ray has little value as a screening tool for either OLD or HF. Chest x-ray findings in OLD patients are usually normal in the early stages of the disease. Late-stage OLD chest x-ray findings include hyperinflation, enlarged retrosternal airspace, low flattened diaphragms, a paucity of vascularity in the peripheral lung fields, pulmonary artery prominence, and the bullous lesions of emphysema. 6 The heart is often noted to have a teardrop shape. Chronic HF patients often have normal chest x-ray findings, which, unfortunately, can lead clinicians to believe that HF is not present. Nonspecific abnormalities such as cardiomegaly and a globular cardiac silhouette may be seen and, on occasion, pulmonary edema and pleural effusions are noted. 16 The real value of the chest x-ray is its ability to rule out other causes of respiratory symptoms, such as pneumonia and pleural effusions.
An electrocardiogram is not critical to the initial workup but is helpful to rule out arrhythmias that can exacerbate symptoms and predict complications.
14 Electrocardiogram findings are generally normal in the early stages of OLD; however, in advanced stages, the presence of peaked P waves, decreased QRS voltage, and right axis deviation may be noted. During acute exacerbation of COPD, supraventricular arrhythmias are common. Electrocardiogram changes in acute severe asthma include right bundle branch block, right axis shift, p-pulmonale, and right ventricular strain. 6 For patients receiving therapy for asthma, sinus tachycardia is often present because of the consequences of sympathomimetic medications and theophylline. During acute exacerbations of asthma, premature ventricular contractions are periodically noted, yet other atrial arrhythmias rarely occur.
Simple office spirometry is the most valuable tool for the screening, diagnosis, and staging of OLD. This is very helpful during the initial HF workup to determine the presence and extent of coexisting pulmonary disease. 5 The 2 most important values when assessing for OLD are the forced expiratory volume in 1 second (FEV 1 ) and the ratio between the FEV 1 and the forced vital capacity (FVC). Based on these 2 values, the severity of COPD can be classified. Table 1 shows values denoting the level of impairment. Severity of COPD should be classified formally, with appropriate pharmacological intervention, according to the GOLD Guidelines. 10 In the HF patient with asthma, the peak expiratory flow rate (PEFR) is used to predict the severity of the inflammation and bronchial constriction. PEFR less than 50% of the patient's personal best predicts severe constriction and requires therapy for an acute exacerbation. Moderate disease is present when PEFR is 60% to 80% of the patient's personal best and mild disease is defined by PEFR greater than or equal to 80% of that predicted. 8 When performing spirometry, it is important to schedule the procedure in such a way that the patient does not use long-or shortacting bronchodilators or inhale steroid medications that day. If the patients take salmeterol, formoterol, or fluticasone/salmeterol combination, they should not take their evening dose prior to the day of the scheduled appointment. Instruct patients not to smoke, especially not in the 8 to 12 hours prior to the procedure. Midway through the test, the patient will receive a short-acting beta2-agonist and repeat the breathing maneuvers. In pure asthma, the decrease in FEV 1 may be fully reversible (or >12% change). 6 The FEV 1 /FVC ratio is likely to be proportional. Spirometry should be performed when the patient is asymptomatic or at a chronic stable state. A pulse oximetry reading should be recorded during this time to mark the patient's normal chronic status. During episodes of exacerbation, these recorded values will serve as levels to be used for comparison.
A thorough lab evaluation, including urinalysis, complete blood cell count, blood urea nitrogen, creatinine level or clearance, electrolytes, and liver and thyroid function tests, should be done to rule out noncardiopulmonary causes of dyspnea. 16 Noncardiopulmonary etiologies include anemia, renal disease (acidosis), chronic liver disease (small arteriovenous shunts occurring at the lung bases), endocrine abnormalities (particularly hyperthyroidism), and early sepsis with bacteremia (dyspnea may be the first manifestation of sepsis in elders).
The recent availability of the B-type natriuretic peptide (BNP) assay has given providers a valuable tool to use in the differential workup of dyspnea. BNP is a cardiac neurohormone secreted by the cardiac ventricles in response to stretch from volume expansion, ventricular overload, and an increase in wall tension. 16 BNP levels are typically elevated during an acute HF decompensation and can be a reliable tool for the diagnosis of latent HF in patients with comorbid pulmonary disease. The BNP Multinational Study revealed a 20% increase in the detection of new onset or previously undiagnosed HF in patients with presumed bronchospasm due to lung disease.
14 BNP levels have shown modest elevation in patients with cor pulmonale, and the lack of BNP elevation has been noted in the presence of moderate elevations in pulmonary arterial pressure in patients with isolated COPD. 17 The BNP assay has been found to be particularly useful in the emergent evaluation of dyspnea. Maisel et al 18 studied 1586 patients presenting with acute dyspnea to the emergency department; BNP levels were measured with a bedside assay and the clinical diagnosis of HF was adjudicated by 2 independent cardiologists who were blinded to the results of the BNP assay. A BNP level higher than 100 pg/mL had a sensitivity of 90%, a specificity of 76%, and an accuracy of 83% in differentiating HF from other causes of dyspnea. In a study looking at hospital readmission rates for patients with either HF or pulmonary disease, Wu et al 19 found that implementation of BNP testing in the emergency department reduced the readmission rates for these patients, presumably because of a decrease in diagnostic ambiguities in the initial diagnosis of HF or pulmonary disease.
Management of Acute Exacerbation of OLD in the HF Patient
The HF patient presenting with a moderate-tosevere exacerbation of asthma has respirations that reflect a decrease in PEFR and are in excess of 30 breaths per minute. The patient often will refuse or be unable to lie supine. Heart rate ranges from 100 to 120 beats per minute. Wheezing may be noted on inspiration and expiration, or, more ominously, not at all. Two objective markers used to determine the severity of the attack are accessory muscle use with chest retraction and the degree of pulsus paradoxus. 9 Severe exacerbations as defined in the asthma guidelines show PEFR less than 50% of the predicted value, and are often between 25% to 30% in the emergency setting. Arterial blood gases need to be assessed for the presence of hypercapnea. If respiratory arrest is not impending, the patient is given nebulized high-dose beta2-agonist and anticholinergic treatment every 20 minutes or continuously for 1 hour. Oxygen is given to achieve saturation of 90% or more. Oral or intravenous (IV) systemic corticosteroids are also given. If there is no improvement in symptoms, the patient is admitted and the aforementioned treatment is continued with vigilant reassessment. Should severe symptoms continue (ie, FEV 1 < 50%, PCO 2 ≥ 42 mm Hg, drowsiness, confusion), intubation and mechanical ventilation are provided to prevent respiratory arrest. 9 Typical discharge medications include high-dose inhaled corticosteroids, a long-acting beta2-agonist, inhaled anticholinergics, and a tapering regimen of oral systemic corticosteroids. A leukotriene inhibitor may or may not be prescribed.
In the instance of acute exacerbation of COPD, the HF patient will complain of worsening dyspnea and increased sputum purulence, viscosity, and volume. Exacerbation often follows an upper respiratory tract infection within a week, fever without any other apparent cause, or an increased incidence of cough and wheezing. 3 Respiratory rate and heart rate can be as high as 20% above baseline. In patients with moderate-to-severe COPD, sputum cultures typically reveal nonpathogenic bacteria. A chest x-ray is useful but may yield positive results in only 15% of cases. Assessment of arterial blood gases is essential to determine the presence of hypercapnea. Blood gases are also used to monitor pH in response to oxygen therapy.
Noninvasive positive pressure ventilation is beneficial for patients experiencing CO 2 retention and respiratory muscle fatigue. During exacerbation of COPD, dynamic hyperinflation occurs, placing these patients at high risk of respiratory failure. Noninvasive positive pressure ventilation decreases much of the work of breathing and often averts the need for invasive mechanical ventilation. It is during the use of noninvasive positive pressure ventilation that antibiotic therapy, IV corticosteroids, treatment with nebulized beta2-agonists, and anticholinergic medications are able to work effectively to decrease bronchial inflammation. 6 Mortality in these patients is compounded by the presence of coexisting HF. In patients with hypercapnea, the readmission rate within 6 months of the exacerbation is 50%. Worse yet, if the patient required treatment in the ICU, mortality approaches 50%. 4 A common problem in HF patients with coexisting OLD is the delay in seeking treatment for their symptoms. In an effort to forestall an additional clinic appointment or because of fear of hospitalization, patients will self-treat at home, attributing their dyspnea to an erroneous etiology. These patients should be taught to seek immediate attention when dyspnea is not quickly relieved by their usual care measures (ie, extra diuretic, rescue bronchodilator); otherwise, symptoms may progress to an acute stage.
Pharmacologic Management of Concomitant Chronic Disease
The pharmacologic regimens for HF and OLD are complex, with drugs for each condition potentially affecting the other condition. The following section highlights the important effects of drugs commonly used to treat these 2 illnesses.
Bronchodilators
Two categories of bronchodilators are often used in a combined effort to increase airflow. Anticholinergic agents are the medications of choice and are administered via a nebulized preparation or through use of a metered dose inhaler. They can be safely combined with short-acting beta2-agonists. There are long-acting (12 hours) preparations of both beta2-agonists and anticholinergics, which can improve medication compliance and decrease the use of short-acting beta2-agonists. Short-acting beta2-agonists can then be reserved for episodes of breakthrough dyspnea. Side effects from inhaled anticholinergic medications are typically mild and few. Side effects of inhaled beta2-agonists include tremors, cephalgia, and palpitations. Elevations in heart rate and blood pressure have also been reported.
Some studies have shown a correlation between bronchodilator use and worsening HF with increased mortality, and it has been suggested that further research should be conducted to rule out the existence of a causal relationship. 15, 20 The presence of the correlation prompts the following questions: (1) Is the patient increasing bronchodilator use because of confusion between the dyspnea of OLD and the dyspnea of HF? (2) Is the beta2-agonist providing temporary relief from the symptoms of left-ventricular systolic dysfunction, causing the patient to forestall seeking treatment for HF? (3) Do the physiological effects from beta2-agonists use actually participate in the cascade of events in worsening HF? In the absence of confirmatory data, it is essential and prudent that clinicians assess the frequency of use of beta2-agonists in HF patients.
Corticosteroids
Airway inflammation is greatly minimized by inhaled topical corticosteroids, with few systemic effects. These medications can be administered via a metered dose inhaler or by dry powder inhaler preparations. Use of high-dose inhaled corticosteroids has shown the capacity to suppress the hypophyseal-pituitaryadrenal axis; however, doses must exceed 1000 g/d. 6 Combined preparations of dry powder inhaler corticosteroids with long-acting beta2-agonists are available for use on a 12-hour basis.
IV and oral corticosteroids are used during an acute exacerbation of OLD and slowly tapered during the resolution of the episode; however, some patients are maintained on low daily doses of oral corticosteroid therapy because of their poor response to inhaled preparations. This therapy is provided only after therapeutic response is noted via documented improvement in lung function. The lowest maintenance dose is utilized and periodic efforts are made to decrease and discontinue the therapy, because of the many systemic adverse effects of therapy.
One of the major concerns with the use of corticosteroids in HF patients is fluid retention, which can lead to acute decompensation. If patients require corticosteroids for treatment of OLD, they need close monitoring, with special attention to salt restriction and daily monitoring of symptoms and weight. Additional diuretics may be indicated temporarily. 13 
Cromolyn Sodium and Leukotriene Modifiers
Both cromolyn sodium and leukotriene modifiers are used to control asthma and prove especially useful in preventing allergen-induced bronchospasm and exercise-induced asthma. They have favorable safety profiles and thus are not likely to interfere with the patient's HF regimen.
Theophylline
Theophylline is used in asthma control as third-line therapy. 8 Routine use is much less common in lieu of the highly efficacious and safe armamentarium of inhaled bronchodilators available. In elders, theophylline is associated with increased adverse effects primarily due to toxicity and medication interactions, providing little symptomatic benefit. 21 Theophylline is periodically used in the acute care setting in patients with a failed response to an aggressive 24-to 48-hour regimen of systemic corticosteroids, beta2-agonists, and anticholinergic therapy. It should also be noted that there exists a subgroup of poorly controlled, severe asthmatic patients who respond favorably to theophylline as part of their medication regimen. These patients decompensate when the dose is titrated downward in an attempt to withdraw the medication.
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Diuretics
Loop diuretics should be used with caution in HF patients with OLD. Electrolytes need to be monitored closely to avoid metabolic alkalosis, due to increased minute ventilation in COPD patients, resulting in a decreased respiratory drive. 4 
Digoxin
Digitalis should be used with caution in COPD patients with right ventricular failure because of its potential for causing pulmonary vasoconstriction and decreased venous return and cardiac output. It is also associated with increased arrhythmias in COPD patients secondary to hypoxia and acidosis. 
Angiotensin-Converting Enzyme Inhibitors
Angiotensin-converting enzyme inhibitors are of benefit in HF patients with COPD as they decrease pulmonary hypertension and airway constriction. They are useful in the treatment of hypertension in patients with asthma. In susceptible patients, the development of an angiotensin-converting enzyme inhibitor cough could precipitate bronchospasm and airway hypersensitivity, leading to a serious adverse event. 4 For these patients, an angiotensin receptor antagonist would be an acceptable alternative.
A cough is difficult to evaluate in the HF patient with OLD. Unless there is a strong suspicion for bronchospasm, it would be prudent to first consider the cough to be due to volume overload and treat accordingly with diuretics. If the patient is indeed euvolemic, other causes, such as an angiotensin-converting enzyme inhibitor cough or etiologies from OLD, should be considered with appropriate treatments instituted.
Beta-Adrenergic Blockers
Beta-adrenergic blockers have traditionally been avoided in patients with OLD because of concerns about precipitating or worsening bronchospasm; however, as noted, bronchospasm in HF patients may reflect volume overload rather than primary pulmonary disease. As beta-adrenergic blockers are a key element in the treatment of HF, they should be tried, if at all feasible, in patients with OLD. There is evidence to support the use of beta-blocker therapy in HF patients with mild-to-moderate OLD in the absence of bronchospasm. 21 Golden et al 22 studied 47 HF patients on beta agonist therapy at entry to a HF treatment program. After adequate dosing of diuretics and angiotensinconverting enzyme inhibitors or angiotensin II receptor blockers, beta agonists were stopped and beta blockade was initiated and up-titrated. At a mean follow-up of 8.7 months, it was found that only 2% of patients had stopped beta-blocker therapy because of drug intolerance, 2% of patients had died, and 15% of patients were hospitalized for cardiovascular causes-similar outcomes to those reported in betablocker trials that have excluded these patients. These authors recommended that HF patients treated empirically with beta agonists without spirometry evidence of reversible airway disease should not be excluded from consideration for beta-blocker therapy.
In moderate-to-severe COPD and asthma, risks and benefits need to be seriously discussed with the patient. Current spirometry information is helpful when making these decisions. If prescribed, shortacting agents should be tried first so that the effects will dissipate quickly if problems occur. Further, if beta blockers are prescribed, optimal treatment with bronchodilators should be a priority.
Conclusion
As practitioners encounter the epidemic of chronic disease and the growing number of elder Americans, the treatment of HF patients with pulmonary comorbidities will be highly prevalent. Because OLD is associated with higher morbidity and poor outcomes in HF patients, clinicians must not only be vigilant in the recognition of both chronic conditions but also be dedicated to the detection and treatment of the underlying cause for decompensation.
